Drug Eluting Stent News and Research

RSS

A drug-eluting stent (DES) is a coronary stent (a scaffold) placed into narrowed, diseased coronary arteries that slowly releases a drug to block cell proliferation. This prevents fibrosis that, together with clots (thrombus), could otherwise block the stented artery, a process called restenosis.

Steroids and antihistamines alleviate clopidogrel-related allergic reaction symptoms

A clinical study of cardiac patients who suffered an allergic reaction to the widely-prescribed drug clopidogrel, also known by the pharmaceutical name Plavix, found that treatment with a combination of steroids and antihistamines can alleviate the allergic reaction symptoms thereby allowing patients to remain on the drug, say doctors from Thomas Jefferson University Hospital.

30 Mar 2009

Drug-eluting stents found to be safer and superior to bare metal stents

Drug-eluting stents were safe and superior to bare metal stents in preventing death and heart attacks among 262,700 "real-world" patients enrolled in a nationwide registry of cardiovascular disease, according to researchers from Duke University Medical Center.

29 Mar 2009

Trial reinforces safety and efficacy of Boston Scientific's two drug-eluting stent platforms

Boston Scientific Corporation has welcomed three-year results from the SPIRIT II Clinical Trial and a pooled meta-analysis of two-year data from the SPIRIT II and III Trials.

29 Mar 2009

Saving limbs with drug-eluting stents

Attempts to treat critical limb ischemia in peripheral arterial disease (PAD) patients with below-the-knee angioplasty are still thwarted by restenosis (the re-narrowing of the artery at the site of angioplasty or stenting), the need for repeat treatments and the continued progression of atherosclerotic disease, leading to tissue death (gangrene) and amputation.

11 Mar 2009

Boston Scientific launches Taxus Liberte drug-eluting stent in Japan

Boston Scientific Corporation has announced the launch of its TAXUS Liberte Paclitaxel-Eluting Coronary Stent System in Japan.

3 Mar 2009

Drug-coated stents less risky for heart bypass patients

Coronary bypass surgery may carry less risk of serious complications if stents coated with a drug that suppresses cell growth are used in the procedure rather than bare-metal stents, UT Southwestern Medical Center researchers and colleagues have found.

23 Jan 2009

Drug eluting stents provide better outcomes that bare metal stents in angioplasty

Patients receiving drug eluting stents (DES) - stents coated with medication to prevent narrowing of the artery - as part of an angioplasty had better outcomes one year later than patients with bare metal stents, according to a new study to be published in CMAJ.

18 Dec 2008

Abbott starts trial of 2.25 mm stent system

Abbott has announced the start of SPIRIT Small Vessel, a clinical trial evaluating a 2.25 mm size of the XIENCE V Everolimus Eluting Coronary Stent System.

17 Dec 2008

Cell-coated stent as effective as drug-coated ones

A stent that entices artery-lining cells to coat it works as well or better than drug-eluting stents in keeping arteries open in coronary heart disease patients, according to two research studies presented at the American Heart Association's Scientific Sessions 2008.

11 Nov 2008

FDA approves second-generation TAXUS Liberte Paclitaxel-Eluting Coronary Stent System

Boston Scientific Corporation has announced it has received approval from the U.S. Food and Drug Administration (FDA) to market its second-generation TAXUS Liberte Paclitaxel-Eluting Coronary Stent System.

12 Oct 2008

New generation drug-eluting stent demonstrates equivalent efficacy to market leader in 'real world'

In the first study of its kind, a drug-eluting stent (DES) with a biodegradable polymer applied only to the outer surface has been demonstrated as safe and effective as one of the most established and widely used types of DES with a durable polymer, in equivalent conditions to everyday clinical practice.

1 Sep 2008

Safer, more effective stents will be available next week for patients with clogged arteries

Wake Forest University Baptist Medical Center will be one of the first medical centers in the region to begin using a new generation of drug-coated stents next week following a major study and the Food and Drug Administration's approval of their use.

3 Jul 2008

Drug-releasing coronary artery stent use linked with decrease in procedures to unblock coronary arteries

The widespread adoption of the use of drug-releasing coronary artery stents into routine practice is associated with a decrease in the need for repeat procedures to unblock coronary arteries and also do not appear to increase the risk of death, compared to bare-metal stents, according to a study in the June 25 issue of JAMA, the Journal of the American Medical Association

24 Jun 2008

Two Penn studies show drug-eluting stents outperform bare metal stents

The more than ten million Americans who've received drug-eluting stents to open their blocked coronary arteries have a bright future, according to new research from the University of Pennsylvania School of Medicine.

22 May 2008

Study finds new generation of drug-coated stent benefits heart patients

A two-year study comparing a new generation drug-coated stent, XIENCE, with a currently used drug eluting stent, TAXUS, has found that the XIENCE stent had superior benefits in more than 1,000 patients and is better at keeping the arteries of chest pain patients clear of blood clots.

15 May 2008

Investigational treatment for advanced widespread emphysema

Researchers at Suburban Lung Associates and the Chicago Chest Center recently announced the start of the EASE (Exhale Airway Stents for Emphysema) Trial to explore an investigational treatment for advanced widespread emphysema.

2 Apr 2008

Study results on novel drug-eluting stent coated with a biodegradable polymer

"Real-world" use of a novel drug-eluting stent coated with a biodegradable polymer is associated with good clinical outcomes, according to one-year data from a large international registry.

1 Apr 2008

Largest ever analysis of DES data demonstrates safety, efficacy in on-and-off-label use

The Cardiovascular Research Foundation (CRF) will present results of the largest meta-analysis to date comparing mortality rates for drug-eluting stents (DES) versus bare metal stents (BMS) at the Drug-Eluting Stent Revolution VII meeting tomorrow evening in Chicago.

31 Mar 2008

Study gives nod to drug-eluting stents in heart attack

Although drug-eluting stents have become widely used for the treatment of stable coronary artery disease, many cardiologists choose bare-metal stents for patients with heart attack, or myocardial infarction (MI), citing conflicting data about the safety and effectiveness of drug-eluting stents in this patient group.